178 related articles for article (PubMed ID: 22638813)
1. The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats.
Alvers KM; Beckmann JS; Zheng G; Crooks PA; Dwoskin LP; Bardo MT
Psychopharmacology (Berl); 2012 Nov; 224(2):255-62. PubMed ID: 22638813
[TBL] [Abstract][Full Text] [Related]
2. The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats.
Beckmann JS; Denehy ED; Zheng G; Crooks PA; Dwoskin LP; Bardo MT
Psychopharmacology (Berl); 2012 Mar; 220(2):395-403. PubMed ID: 21938414
[TBL] [Abstract][Full Text] [Related]
3. Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats.
Wilmouth CE; Zheng G; Crooks PA; Dwoskin LP; Bardo MT
Pharmacol Biochem Behav; 2013 Nov; 112():29-33. PubMed ID: 24075974
[TBL] [Abstract][Full Text] [Related]
4. Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo.
Meyer AC; Neugebauer NM; Zheng G; Crooks PA; Dwoskin LP; Bardo MT
J Neurochem; 2013 Oct; 127(2):187-98. PubMed ID: 23875705
[TBL] [Abstract][Full Text] [Related]
5. New Scaffold for Lead Compounds to Treat Methamphetamine Use Disorders.
Lee NR; Zheng G; Crooks PA; Bardo MT; Dwoskin LP
AAPS J; 2018 Feb; 20(2):29. PubMed ID: 29427069
[TBL] [Abstract][Full Text] [Related]
6. GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine.
Horton DB; Nickell JR; Zheng G; Crooks PA; Dwoskin LP
J Neurochem; 2013 Oct; 127(2):177-86. PubMed ID: 23875622
[TBL] [Abstract][Full Text] [Related]
7. GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine.
Lee NR; Zheng G; Leggas M; Janganati V; Nickell JR; Crooks PA; Bardo MT; Dwoskin LP
J Pharmacol Exp Ther; 2019 Nov; 371(2):526-543. PubMed ID: 31413138
[TBL] [Abstract][Full Text] [Related]
8. GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2.
Nickell JR; Siripurapu KB; Horton DB; Zheng G; Crooks PA; Dwoskin LP
Eur J Pharmacol; 2017 Jan; 795():143-149. PubMed ID: 27986625
[TBL] [Abstract][Full Text] [Related]
9. Varenicline and GZ-793A differentially decrease methamphetamine self-administration under a multiple schedule of reinforcement in rats.
Kangiser MM; Dwoskin LP; Zheng G; Crooks PA; Stairs DJ
Behav Pharmacol; 2018 Feb; 29(1):87-97. PubMed ID: 28863003
[TBL] [Abstract][Full Text] [Related]
10. The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.
Nickell JR; Siripurapu KB; Vartak A; Crooks PA; Dwoskin LP
Adv Pharmacol; 2014; 69():71-106. PubMed ID: 24484975
[TBL] [Abstract][Full Text] [Related]
11. Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.
Horton DB; Siripurapu KB; Zheng G; Crooks PA; Dwoskin LP
J Pharmacol Exp Ther; 2011 Oct; 339(1):286-97. PubMed ID: 21778282
[TBL] [Abstract][Full Text] [Related]
12. Environmental enrichment reduces methamphetamine cue-induced reinstatement but does not alter methamphetamine reward or VMAT2 function.
Hofford RS; Darna M; Wilmouth CE; Dwoskin LP; Bardo MT
Behav Brain Res; 2014 Aug; 270():151-8. PubMed ID: 24821405
[TBL] [Abstract][Full Text] [Related]
13. Prevention of drug priming- and cue-induced reinstatement of MDMA-seeking behaviors by the CB1 cannabinoid receptor antagonist AM251.
Nawata Y; Kitaichi K; Yamamoto T
Drug Alcohol Depend; 2016 Mar; 160():76-81. PubMed ID: 26796595
[TBL] [Abstract][Full Text] [Related]
14. Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.
Nickell JR; Krishnamurthy S; Norrholm S; Deaciuc G; Siripurapu KB; Zheng G; Crooks PA; Dwoskin LP
J Pharmacol Exp Ther; 2010 Feb; 332(2):612-21. PubMed ID: 19855096
[TBL] [Abstract][Full Text] [Related]
15. The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats.
Beckmann JS; Siripurapu KB; Nickell JR; Horton DB; Denehy ED; Vartak A; Crooks PA; Dwoskin LP; Bardo MT
J Pharmacol Exp Ther; 2010 Dec; 335(3):841-51. PubMed ID: 20805303
[TBL] [Abstract][Full Text] [Related]
16. Pyrrolidine analogs of GZ-793A: synthesis and evaluation as inhibitors of the vesicular monoamine transporter-2 (VMAT2).
Penthala NR; Ponugoti PR; Nickell JR; Deaciuc AG; Dwoskin LP; Crooks PA
Bioorg Med Chem Lett; 2013 Jun; 23(11):3342-5. PubMed ID: 23597792
[TBL] [Abstract][Full Text] [Related]
17. Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2.
Nickell JR; Zheng G; Deaciuc AG; Crooks PA; Dwoskin LP
J Pharmacol Exp Ther; 2011 Mar; 336(3):724-33. PubMed ID: 20876747
[TBL] [Abstract][Full Text] [Related]
18. Oxytocin treatment in the prelimbic cortex reduces relapse to methamphetamine-seeking and is associated with reduced activity in the rostral nucleus accumbens core.
Everett N; Baracz S; Cornish J
Pharmacol Biochem Behav; 2019 Aug; 183():64-71. PubMed ID: 31202809
[TBL] [Abstract][Full Text] [Related]
19. Nicotine- and cocaine-triggered methamphetamine reinstatement in female and male Sprague-Dawley rats.
Pittenger ST; Chou S; Barrett ST; Catalano I; Lydiatt M; Bevins RA
Pharmacol Biochem Behav; 2017 Aug; 159():69-75. PubMed ID: 28712749
[TBL] [Abstract][Full Text] [Related]
20. Attenuation of methamphetamine seeking by the mGluR2/3 agonist LY379268 in rats with histories of restricted and escalated self-administration.
Kufahl PR; Watterson LR; Nemirovsky NE; Hood LE; Villa A; Halstengard C; Zautra N; Olive MF
Neuropharmacology; 2013 Mar; 66():290-301. PubMed ID: 22659409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
